## The YODA Project Research Proposal Due Diligence Assessment

VODA Project (Protocol) ID:   2018-2801	Part 1: General Information			
Product Name: Abiraterone acetate  Therapeutic Area: Oncology  Product Class: CYP17 Inhibitor  Condition(s) Studied: Prostatic Neoplasms  Protocol Number(s) and Title(s): NCT00638690/ COU-AA-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198/COU-AA-302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Yes partner has agreed to share clinical trial data.  Comments: Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments: Yes Comments: Y	YODA Project (Protocol) ID: 2018-2801			
Therapeutic Area: Oncology  Product Class: CYP17 inhibitor  Condition(s) Studied: Prostatic Neoplasms  Protocol Number(s) and Title(s): Prostatic Neoplasms  NCT00638690/ COU-AA-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198/COU-AA-302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Yes partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be Yes converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by Yes regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a Presults and trial trial and trial has been completed for a Presults published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the Yes requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No  Participant-level data is appropriate for the proposed analysis. No  Participant-level data is appropriate for the proposed analysis. No	Date:	7 March 2018		
Product Class: CYP17 inhibitor  Condition(s) Studied: Prostatic Neoplasms  Protocol Number(s) and Title(s): Prostatic Neoplasms  NCT00638690/ COU-AA-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198/COU-AA-302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Presponse of the Presp	Product Name:			
Product Class: CYP17 inhibitor  Condition(s) Studied: Prostatic Neoplasms  Protocol Number(s) and Title(s): Prostatic Neoplasms  NCT00638690/ COU-AA-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198/COU-AA-302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Presponse of the Presp	Therapeutic Area:			
Prostatic Neoplasms   Protocol Number(s) and   Title(s):   Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus   Prednisone in Patients With Metastatic Castration-Resistant Prostate   Cancer Who Have Failed Docetaxel-Based Chemotherapy   NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus   Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy   NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus   Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer      Part 2: Data Availability   Part Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer   Presponse:	•			
Protocol Number(s) and Title(s):    Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer    Part 2: Data Availability				
Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Yes partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be Yes converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the Yes requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No				
Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability Question:  Response:  Data Holder has authority to provide clinical trial data or development yes partner has agreed to share clinical trial data. Comments:  Data Holder has shareable electronic clinical trial data or data can be yes converted to electronic format. Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality. Comments:  The product and relevant indication studied has either been approved by yes regulators in the US and EU, or terminated from development. Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Pes A similar analysis is underway or completed/pending disclosure by Janssen.	1			
Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question:  Part Availability  Question:  Data Holder has authority to provide clinical trial data or development Yes Part and trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be Yes converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current Yes HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by Yes regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the Yes requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Yes A similar analysis is underway or completed/pending disclosure by Janssen.		· · · · · · · · · · · · · · · · · · ·		
NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Yes partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be Yes converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by Yes regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen.				
Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question:  Response:  Data Holder has authority to provide clinical trial data or development yes partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be onverted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Yes  A similar analysis is underway or completed/pending disclosure by Janssen.	Cancer with have railed bocetaxer-based chemotherapy			
Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer  Part 2: Data Availability  Question:  Response:  Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Yes  A similar analysis is underway or completed/pending disclosure by Janssen.	NCT00887198/COU-AA-302- A Phase 3, Randomized, Double-blind,			
Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development yes partner has agreed to share clinical trial data.  Comments: Data Holder has shareable electronic clinical trial data or data can be yes converted to electronic format.  Comments: De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments: The product and relevant indication studied has either been approved by yes regulators in the US and EU, or terminated from development.  Comments: Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No	Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus			
Part 2: Data Availability  Question: Response:  Data Holder has authority to provide clinical trial data or development Yes partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Yes A similar analysis is underway or completed/pending disclosure by Janssen.	Prednisone in Asymptomatic or Mildly Symptomatic		natic Patients With	
Question:  Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  No A similar analysis is underway or completed/pending disclosure by Janssen.		Metastatic Castration-Resistant Prostate Cancer	•	
Question:  Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  No A similar analysis is underway or completed/pending disclosure by Janssen.				
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No  Participant-level data is appropriate for the proposed analysis.  No  A similar analysis is underway or completed/pending disclosure by Janssen.				
partner has agreed to share clinical trial data.  Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Yes A similar analysis is underway or completed/pending disclosure by Janssen.	•		•	
Comments:  Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.	· · ·		Yes	
Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  No A similar analysis is underway or completed/pending disclosure by Janssen.	·			
converted to electronic format.  Comments:  De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  Yes  A similar analysis is underway or completed/pending disclosure by Janssen.				
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No				
HIPAA and EU criteria allows protection of participant privacy and confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No	Comments:	,		
confidentiality.  Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No	De-identification and redaction of clinical trial data in accordance with current  Yes			
Comments:  The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No				
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No				
regulators in the US and EU, or terminated from development.  Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No  Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No				
Comments:  Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  No Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.	-	res		
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).  Comments:  Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question:  Response:  Summary-level CSR data is appropriate for the proposed analysis.  Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No		terminated from development.		
Based on the responses to the above Data Availability Questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No		e clinical trial and trial has been completed for a	Yes	
Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No	· · · · · · · · · · · · · · · · · · ·			
Part 3: Data Availability Summary  Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No				
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.  Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No	Comments:			
Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No Participant-level data is appropriate for the proposed analysis. Yes A similar analysis is underway or completed/pending disclosure by Janssen. No	Part 3: Data Availability Summary			
Part 4: Proposal Review  Question: Response:  Summary-level CSR data is appropriate for the proposed analysis. No  Participant-level data is appropriate for the proposed analysis. Yes  A similar analysis is underway or completed/pending disclosure by Janssen. No			Yes	
Question:Response:Summary-level CSR data is appropriate for the proposed analysis.NoParticipant-level data is appropriate for the proposed analysis.YesA similar analysis is underway or completed/pending disclosure by Janssen.No	requested clinical trial data can be made available for data sharing.			
Question:Response:Summary-level CSR data is appropriate for the proposed analysis.NoParticipant-level data is appropriate for the proposed analysis.YesA similar analysis is underway or completed/pending disclosure by Janssen.No				
Summary-level CSR data is appropriate for the proposed analysis.  Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No		•		
Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.  No		7		
A similar analysis is underway or completed/pending disclosure by Janssen. No				
	Comments:	or completed/pending disclosure by Janssen.	INO	